Cyxone
0,046 SEK -5,21%Vær den første som følger denne virksomhed
Cyxone is a biotechnology company. The company's specialist expertise is found in the development of pharmaceuticals with a focus on plant protein as a base. The pharmaceutical is intended to be used mainly in the treatment of immune-related diseases, and the products are based on cyclotide technology. The purpose is that the pharmaceutical will be used in the treatment of multiple sclerosis and rheumatoid arthritis. Cyxone's head office is located in Malmö.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
CYXO
Daglig lav / høj pris
0,044 / 0,056
SEK
Markedsværdi
9,82 mio. SEK
Aktieomsætning
266,16 t SEK
Volumen
5,5 mio.
Seneste videoer
Finanskalender
Delårsrapport
29.08.2024
Delårsrapport
07.11.2024
Årsrapport
25.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Avanza Pension | 5,8 % | 5,8 % |
Ivar Nordqvist | 4,2 % | 4,2 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Cyxone provides an update on its research and development program
Kjell Stenberg new CEO in Cyxone AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools